A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy

Shu Meguro, Motoaki Sano, Toshihide Kawai, Tomohiro Matsuhashi, Satoshi Mogi, Keiichi Fukuda, Hiroshi Itoh, Yoshihiko Suzuki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

There has been concern as to whether dipeptidyl peptidase-4 (DPP-4) inhibitors can be used safely in patients with relatively good glycemic control. This study, approved by the institutional review board of Hanzoumon Diabetes City Atlas Clinic, examined whether DPP-4 inhibitor sitagliptin could safely achieve good glycemic control without severe hypoglycemia by employing the "added food" concept. The subjects were 60 patients (46 men and 14 women) with type 2 diabetes who started sitagliptin therapy during a 1-month period from December 15, 2009 to January 15, 2010. They were recommended to have added food between meals to prevent hypoglycemia, while maintaining the same daily calorie intake. HbA1c decreased from 7.1 ± 1.2 to 6.5 ± 0.6 after 6 months of sitagliptin treatment (p < 0.001). In patients with a baseline HbA1c <7, it decreased from 6.5 ± 0.3 to 6.1 ± 0.4 (p < 0.001). Systolic blood pressure was significantly reduced from 127.7 ± 17.0 to 122.7 ± 17.9 mmHg in the patients with a baseline HbA1c < 7 (p 0.018). However, body weight increased by approximately 900 g and high-density lipoprotein cholesterol decreased significantly from 1.57 ± 0.46 to 1.43 ± 0.35 mmol/L (p < 0.01) in the patients concomitantly receiving sulfonylureas with sitagliptin. Excellent glycemic control was achieved by sitagliptin treatment together with the added food concept. However, combined use of sitagliptin with sulfonylureas requires attention to weight gain and the lipid profile. Further clinical studies will elucidate whether sitagliptin can decrease cardiovascular events as well as normalizing blood glucose and lowering the blood pressure.

Original languageEnglish
Pages (from-to)175-181
Number of pages7
JournalEndocrine Research
Volume37
Issue number4
DOIs
Publication statusPublished - 2012 Nov

Fingerprint

Hypoglycemia
Type 2 Diabetes Mellitus
Diet
Food
Dipeptidyl-Peptidase IV Inhibitors
Blood Pressure
Therapeutics
Atlases
Research Ethics Committees
Sitagliptin Phosphate
HDL Cholesterol
Weight Gain
Meals
Blood Glucose
Body Weight
Lipids

Keywords

  • Cardiovascular events
  • Dipeptidyl peptidase-4 inhibitor
  • Glycemic control
  • Hemoglobin A1c
  • Incretin-based drug
  • Sulfonylurea

ASJC Scopus subject areas

  • Endocrinology

Cite this

A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy. / Meguro, Shu; Sano, Motoaki; Kawai, Toshihide; Matsuhashi, Tomohiro; Mogi, Satoshi; Fukuda, Keiichi; Itoh, Hiroshi; Suzuki, Yoshihiko.

In: Endocrine Research, Vol. 37, No. 4, 11.2012, p. 175-181.

Research output: Contribution to journalArticle

@article{082eaca88ddf4a989cce697fee0a456e,
title = "A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy",
abstract = "There has been concern as to whether dipeptidyl peptidase-4 (DPP-4) inhibitors can be used safely in patients with relatively good glycemic control. This study, approved by the institutional review board of Hanzoumon Diabetes City Atlas Clinic, examined whether DPP-4 inhibitor sitagliptin could safely achieve good glycemic control without severe hypoglycemia by employing the {"}added food{"} concept. The subjects were 60 patients (46 men and 14 women) with type 2 diabetes who started sitagliptin therapy during a 1-month period from December 15, 2009 to January 15, 2010. They were recommended to have added food between meals to prevent hypoglycemia, while maintaining the same daily calorie intake. HbA1c decreased from 7.1 ± 1.2 to 6.5 ± 0.6 after 6 months of sitagliptin treatment (p < 0.001). In patients with a baseline HbA1c <7, it decreased from 6.5 ± 0.3 to 6.1 ± 0.4 (p < 0.001). Systolic blood pressure was significantly reduced from 127.7 ± 17.0 to 122.7 ± 17.9 mmHg in the patients with a baseline HbA1c < 7 (p 0.018). However, body weight increased by approximately 900 g and high-density lipoprotein cholesterol decreased significantly from 1.57 ± 0.46 to 1.43 ± 0.35 mmol/L (p < 0.01) in the patients concomitantly receiving sulfonylureas with sitagliptin. Excellent glycemic control was achieved by sitagliptin treatment together with the added food concept. However, combined use of sitagliptin with sulfonylureas requires attention to weight gain and the lipid profile. Further clinical studies will elucidate whether sitagliptin can decrease cardiovascular events as well as normalizing blood glucose and lowering the blood pressure.",
keywords = "Cardiovascular events, Dipeptidyl peptidase-4 inhibitor, Glycemic control, Hemoglobin A1c, Incretin-based drug, Sulfonylurea",
author = "Shu Meguro and Motoaki Sano and Toshihide Kawai and Tomohiro Matsuhashi and Satoshi Mogi and Keiichi Fukuda and Hiroshi Itoh and Yoshihiko Suzuki",
year = "2012",
month = "11",
doi = "10.3109/07435800.2012.662664",
language = "English",
volume = "37",
pages = "175--181",
journal = "Endocrine Research",
issn = "0743-5800",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy

AU - Meguro, Shu

AU - Sano, Motoaki

AU - Kawai, Toshihide

AU - Matsuhashi, Tomohiro

AU - Mogi, Satoshi

AU - Fukuda, Keiichi

AU - Itoh, Hiroshi

AU - Suzuki, Yoshihiko

PY - 2012/11

Y1 - 2012/11

N2 - There has been concern as to whether dipeptidyl peptidase-4 (DPP-4) inhibitors can be used safely in patients with relatively good glycemic control. This study, approved by the institutional review board of Hanzoumon Diabetes City Atlas Clinic, examined whether DPP-4 inhibitor sitagliptin could safely achieve good glycemic control without severe hypoglycemia by employing the "added food" concept. The subjects were 60 patients (46 men and 14 women) with type 2 diabetes who started sitagliptin therapy during a 1-month period from December 15, 2009 to January 15, 2010. They were recommended to have added food between meals to prevent hypoglycemia, while maintaining the same daily calorie intake. HbA1c decreased from 7.1 ± 1.2 to 6.5 ± 0.6 after 6 months of sitagliptin treatment (p < 0.001). In patients with a baseline HbA1c <7, it decreased from 6.5 ± 0.3 to 6.1 ± 0.4 (p < 0.001). Systolic blood pressure was significantly reduced from 127.7 ± 17.0 to 122.7 ± 17.9 mmHg in the patients with a baseline HbA1c < 7 (p 0.018). However, body weight increased by approximately 900 g and high-density lipoprotein cholesterol decreased significantly from 1.57 ± 0.46 to 1.43 ± 0.35 mmol/L (p < 0.01) in the patients concomitantly receiving sulfonylureas with sitagliptin. Excellent glycemic control was achieved by sitagliptin treatment together with the added food concept. However, combined use of sitagliptin with sulfonylureas requires attention to weight gain and the lipid profile. Further clinical studies will elucidate whether sitagliptin can decrease cardiovascular events as well as normalizing blood glucose and lowering the blood pressure.

AB - There has been concern as to whether dipeptidyl peptidase-4 (DPP-4) inhibitors can be used safely in patients with relatively good glycemic control. This study, approved by the institutional review board of Hanzoumon Diabetes City Atlas Clinic, examined whether DPP-4 inhibitor sitagliptin could safely achieve good glycemic control without severe hypoglycemia by employing the "added food" concept. The subjects were 60 patients (46 men and 14 women) with type 2 diabetes who started sitagliptin therapy during a 1-month period from December 15, 2009 to January 15, 2010. They were recommended to have added food between meals to prevent hypoglycemia, while maintaining the same daily calorie intake. HbA1c decreased from 7.1 ± 1.2 to 6.5 ± 0.6 after 6 months of sitagliptin treatment (p < 0.001). In patients with a baseline HbA1c <7, it decreased from 6.5 ± 0.3 to 6.1 ± 0.4 (p < 0.001). Systolic blood pressure was significantly reduced from 127.7 ± 17.0 to 122.7 ± 17.9 mmHg in the patients with a baseline HbA1c < 7 (p 0.018). However, body weight increased by approximately 900 g and high-density lipoprotein cholesterol decreased significantly from 1.57 ± 0.46 to 1.43 ± 0.35 mmol/L (p < 0.01) in the patients concomitantly receiving sulfonylureas with sitagliptin. Excellent glycemic control was achieved by sitagliptin treatment together with the added food concept. However, combined use of sitagliptin with sulfonylureas requires attention to weight gain and the lipid profile. Further clinical studies will elucidate whether sitagliptin can decrease cardiovascular events as well as normalizing blood glucose and lowering the blood pressure.

KW - Cardiovascular events

KW - Dipeptidyl peptidase-4 inhibitor

KW - Glycemic control

KW - Hemoglobin A1c

KW - Incretin-based drug

KW - Sulfonylurea

UR - http://www.scopus.com/inward/record.url?scp=84866896508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866896508&partnerID=8YFLogxK

U2 - 10.3109/07435800.2012.662664

DO - 10.3109/07435800.2012.662664

M3 - Article

VL - 37

SP - 175

EP - 181

JO - Endocrine Research

JF - Endocrine Research

SN - 0743-5800

IS - 4

ER -